Baxdela

Active Ingredient(s): Delafloxacin
FDA Approved: * June 19, 2017
Pharm Company: * MELINTA THERAPEUTICS INC
Category: Antibiotics

Delafloxacin sold under the brand name Baxdela among others, is a fluoroquinolone antibiotic used to treat acute bacterial skin and skin structure infections.[1] Contents 1 Medical use 2 Adverse effects 3 Interactions 4 Pharmacology 5 Chemistry 6 History 7 References 8 External links Medical use Delafloxacin is indicated to treat adults with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria or adults with community-acq... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Baxdela 450 mg Oral Tablet

NDC: 70842-101

Labeler:

Melinta Therapeutics, Inc

Baxdela 300 mg/10.5ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 70842-102

Labeler:

Melinta Therapeutics, Inc